Clinical Trial

The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 23, 2023 (before its estimated October 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy and safety of TAS-102 combined with bevacizumab as first-line therapy in patients with advanced colorectal cancer who could not tolerate or did not receive combined chemotherapy
Trial Details
NCT Number NCT06092242
Lead Sponsor The Second Affiliated Hospital of Shandong First Medical University
Conditions Colorectal Cancer
Enrollment 50 participants
Start Date 2023-10-15
Primary Completion 2025-10-15 (estimated)
Study Completion 2027-10-15 (estimated)
Updated on ClinicalTrials.gov 2023-10-23